Intel stock extends gains after report of possible U.S. government stake
Director Ralph Alvarez acquired 758 shares of Eli Lilly & Co (NYSE:LLY) on August 13, 2025, at a price of $660.254 per share, in one transaction.
The purchase amounted to a total value of $500472. Following the transaction, Alvarez directly holds 54994.58 shares of Eli Lilly & Co. He also indirectly holds 758 shares by trust.
In other recent news, Eli Lilly reported second-quarter 2025 earnings that surpassed expectations, with both revenue and earnings per share showing significant gains. The company also raised its full-year guidance, reflecting confidence in its ongoing performance. Despite these positive financial results, investor attention has been drawn to clinical trial data for Eli Lilly’s weight loss drug candidate, Orforglipron, which did not meet market expectations. This disappointment led to a reduction in the company’s stock price targets by both Cantor Fitzgerald and Guggenheim, with Cantor setting a new target of $825 and Guggenheim adjusting to $875, though both firms maintained positive ratings. Additionally, Eli Lilly has increased the price of its weight loss drug Mounjaro in the UK by up to 170%, raising the cost of a month’s supply from £122 to £330. In legal developments, the Texas Attorney General has filed a lawsuit against Eli Lilly, accusing the company of bribing healthcare providers to prescribe its medications, specifically targeting its GLP-1 drugs Mounjaro and Zepbound. These recent developments highlight the challenges and opportunities facing Eli Lilly in the pharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.